ASGCT 19th Annual Meeting, Washington DC
5 MAY 2016Presentations and Publications
Read about publications and presentations made by Benitec's scientific team below. For details of Benitec's announcements to NASDAQ, read details in our Investor Centre.2016
Toxicology evaluation of TT-034 demonstrates durable expression in hepatic tissues without long term adverse effects on endogenous miRNA levels
A comparison of scAAV8-TT034 mediated transduction and shRNA expression in human liver biopsy samples versus a chimeric mouse model with humanized liver
ASGCT 19th Annual Meeting, Washington DC
5 MAY 2016
BB-HB-331, a DNA-Directed RNA Interference (ddRNAi) Agent Targeting Hepatitis B Virus (HBV), Can Effectively Suppress HBV In Vitro and In Vivo
ASGCT 19th Annual Meeting, Washington DC
5 MAY 2016
Phase I/IIa Study of TT-034, a DNA-Directed RNA Interference (ddRNAi) Agent Delivered as a Single Administration for the Treatment of Subjects with Chronic Hepatitis C Virus (HCV)
ASGCT 19th Annual Meeting, Washington DC
5 MAY 2016
Gene Therapy Rescues Disease Phenotype in the Oculopharyngeal Muscular Dystrophy Mouse Model
ASGCT 19th Annual Meeting, Washington DC
5 MAY 20162015
Phase I/IIa study of TT-034, a DNA-directed RNA interference agent (ddRNAi) delivered as a single administration for the treatment of subjects with chronic hepatitis C virus (HCV)
The Liver Meeting (AASLD), San Francisco
14 NOV 2015
Toxicology evaluation of TT-034 demonstrates durable expression in hepatic tissues without long term adverse effects on endogenous miRNA levels
The Liver Meeting (AASLD), San Francisco
13 NOV 20152014
Deep Sequencing Insights in Therapeutic shRNA Processing and siRNA Target Cleavage Precision
Molecular Therapy Nucleic Acids. 2014;3(2):e145-. doi:10.1038/mtna.2013.73
1 JAN 2014
In it for the long haul: Vector mediated therapeutics based upon DNA-directed RNA Interference
Drug Discovery World Fall 2014
1 JAN 20142012
In Vitro Characterization of the Activity of PF-05095808, a Novel Biological Agent for Hepatitis C Virus Therapy
Antimicrobial Agents and Chemotherapy. 2012; 56(3):1364-1375. doi:10.1128/AAC.05357-11
1 JAN 2012